Stories from people navigating rectal cancer — diagnosis, treatment, caregiving, and the ordinary days in between.
6 stories
Oncology
The indication covers adults with stage II or III locally advanced rectal cancer that is MSI-H or dMMR, as established with an FDA-authorized test.
Rayan Salih · November 9, 2026 · 6 min
Health Policy
The FDA authorized dostarlimab for eligible adults with stage II or III locally advanced rectal cancer, based on a 154-patient efficacy assessment. Confirmation of long-term clinical benefit is still required.
Rayan Salih · 7 min read
Oncology
Accelerated approval adds dostarlimab as an initial option for selected patients with untreated stage II or III MSI-H or dMMR rectal cancer, making organ preservation an early multidisciplinary decision.
Rayan Salih · 6 min read
Oncology
Accelerated approval makes dostarlimab an initial option for previously untreated stage II or III MSI-H/dMMR rectal cancer, with the possibility of avoiding chemotherapy, radiation and surgery.
Rayan Salih · 6 min read
Oncology
FDA accelerated approval covers selected previously untreated adults with MSI-H or dMMR locally advanced rectal cancer, allowing standard chemoradiation and surgery to be deferred when a complete clinical response is sustained.
Rayan Salih · 7 min read
Oncology
The FDA approval applies to adults with untreated stage II or III locally advanced rectal cancer whose tumors are MSI-H or dMMR. Testing must occur before the initial treatment strategy is fixed.
Rayan Salih · 6 min read
Other conditions
One story a day
One health journey each morning — no advice, no alarm, just company for the road.